Navigation Links
Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
Date:3/3/2009

KVISTGAARD, Denmark, March 3 /PRNewswire-FirstCall/ -- Following the completion of the Phase II clinical development of IMVAMUNE(R), a third-generation smallpox vaccine, Bavarian Nordic has held an end of Phase II meeting with the FDA to discuss the Phase III development. The meeting was a success and there was an open and highly constructive discussion with the FDA.

This meeting represented the first ever formal discussions with the agency to license a vaccine under the new legislation of the animal rule - a new regulatory path which allows the efficacy of products for indications like smallpox to be established in suitable animal efficacy models. This marks a major regulatory milestone in the successful development of IMVAMUNE(R).

The animal efficacy models and phase III protocol have essentially been agreed with the agency - outlining a clear path for licensure of IMVAMUNE(R). Once all protocols have been agreed with the FDA a Vaccines Related Biological Product Advisory Committee (VRBPAC) will be scheduled to ratify the license strategy. This exceptional review path will likely push the initiation of the Phase III studies into late 2010, leading to the submission of a BLA in 2013.

The outcome of the meeting has no impact on the delivery of vaccines to the Strategic National Stockpile (SNS) under the RFP-3 contract with the US government, which is still expected to be initiated in 2009.

In clinical trials to-date, IMVAMUNE(R) has shown to be safe and well tolerated in more than 2,400 people including more than 900 immune compromised people, either infected with HIV or diagnosed with atopic dermatitis. These clinical studies have demonstrated that IMVAMUNE(R) induces a fast and strong immune response, which is comparable to that induced by traditional smallpox vaccines. However, the efficacy of IMVAMUNE(R) cannot be established in the clinic, because smallpox no longer exist
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bavarian Nordics Case Against Oxford BioMedica
2. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
5. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
6. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
7. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
8. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
9. GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research
10. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
11. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... John Madison, Wis. The ... to serve as general director for the WiSys ... technologies. , ,Founded in 2000 as a supplementary organization ... of the other 25 UW System campuses by protecting ...
... 2004, Inc. from Sharon Farmer. In the summer of ... meeting between Senator John Kerry and technology executives in Silicon ... of the presidential campaign, and I had no particular interest ... , ,Six months later, I had the opportunity to interview ...
... amid a group of Midwest technology consultants and you want to get ... work for free? Its an amazing thing. , ,You can ply your ... outstanding resume and all you have to do is hang out a ... and asking you to perform your services for no money. , ,When ...
Cached Biology Technology:WiSys new manager plans system-wide research awareness 2John Kerry talks technology 2John Kerry talks technology 3John Kerry talks technology 4Dont work for free on a maybe someday 2Dont work for free on a maybe someday 3Dont work for free on a maybe someday 4
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... girls exposed to high levels of the pesticide DDT ... to develop hypertension,when they become adults, according to a ... Previous studies have shown that adults exposed ... pressure. But this study, published online March 12 in, ...
... combination of extreme cold temperatures, man-made chemicals and a ... Arctic ozone hole of 2011, a new NASA study ... undergo ozone losses during the winter, the Arctic,s ozone ... Antarctic,s. This is because the three key ingredients needed ...
... was shown that pumpkins and cucumbers can be traced back ... an understanding of Cucurbitaceae evolution and diversity, a new checklist ... information on that family. The study was published in the ... are essential components of a healthy daily diet, not just ...
Cached Biology News:Prenatal exposure to pesticide DDT linked to adult high blood pressure 2NASA pinpoints causes of 2011 Arctic ozone hole 2NASA pinpoints causes of 2011 Arctic ozone hole 3A new checklist confirms Indian origins of pumpkins and cucumbers 2
Standard Fluka For microscopy (Bact., Hist.)...
Request Info...
... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
Special grade: for electrophoresis...
Biology Products: